PSIL
AdvisorShares Psychedelics ETF
PSIL is actively managed to provide exposure to the emerging global psychedelics industry.
International
EQUITY
Active
MANAGEMENT STYLE
$ 50.4 M
ASSETS UNDER MGMT
99 bp
EXPENSES
Fund Basics
| Inception date | Sep 15, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| COMPASS PATHWAYS PLC ADR | 11.9 % |
| DEFINIUM THERAPEUTICS INC | 11.6 % |
| HELUS PHARMA INC ORDINARY SHARES | 9.1 % |
| RELMADA THERAPEUTICS INC | 4.7 % |
| ELI LILLY & CO | 4.7 % |
| ABBVIE INC | 4.5 % |
| NEUROCRINE BIOSCIENCES INC | 4.5 % |
| JOHNSON & JOHNSON | 4.3 % |
| GH RESEARCH PLC | 4.3 % |
| NRX PHARMACEUTICALS INC ORDINARY SHARES | 4.3 % |
Constituent Breakdown
| Number of holdings | 35 |
| Herfindahl-Hirschman Index | 599 |
| Wgt avg mkt cap (mns) | $99,509 |
| Large cap (>$10bn) | 11.9% |
| Mid cap ($2-10bn) | 16.6% |
| Small cap (<$2bn) | 15.1% |
| Developed mkts. | 47.7% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 49.8 % |
 |
IRELAND | 3.5 % |
 |
CANADA | 0.7 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 31.0% | 18.6% | 71.6% | 11.8% | -24.4% | -- | -- | -25.6% |
| Dividend Yield | 0.0% | 11.8% | 10.2% | 4.9% | 2.3% | -- | -- | 2.3% |
| Total Returns | 31.0% | 30.3% | 81.8% | 16.7% | -22.1% | -- | -- | -23.3% | Ann. Volatility | 38.7% | 40.1% | 83.3% | 71.5% | 61.9% | -- | -- | 61.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.25 | 16% |
| MSCI EAFE | 0.99 | 15% |
| MSCI Emg Mkts | 0.52 | 11% |
Liquidity Measures
| Avg. volume (000) | 28 |
| ADV traded (mns) | $1 |
| Turnover | 1.2% |
| Avg. Bid/Ask (% of price) | 0.58% |
Technical Indicators
| 30d moving avg. (EMA) | $23.96 |
| Relative strength (RSI) | 61 |
| MACD/Signal | 0.62/0.56 |
| Bollinger Bands (Upper/Lower) | $25.77/$22.80 |
| Short interest (% of AUM) | 3.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PSIL |
Expenses vs. PSIL |
ALTAR Score™ vs. PSIL |
|---|---|---|---|---|
| MEDX | Horizon Kinetics Medical ETF | 16.9% | -14 bp | -4.6% |
| PJP | Invesco Pharmaceuticals ETF | 16.1% | -42 bp | +0.8% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 15.1% | -39 bp | +0.1% |
| JDOC | JPMorgan Healthcare Leaders ETF | 14.3% | -34 bp | -1.2% |
| VHT | Vanguard Health Care ETF | 13.9% | -90 bp | -0.8% |
| FHLC | Fidelity MSCI Health Care Index ETF | 13.9% | -91 bp | -0.7% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 13.8% | -86 bp | +0.4% |
| IYH | iShares U.S. Healthcare ETF | 13.7% | -59 bp | -0.3% |
| PINK | Simplify Health Care ETF | 13.6% | -49 bp | -5.7% |
| XLV | Health Care Select Sector SPDR | 13.5% | -91 bp | +0.5% |
Risk and Returns: PSIL vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 10/20/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
5.7%
ALTAR SCORE™
27th
PERCENTILE
UNDERWEIGHT
ETFRC RATING
There are 422 funds in the International Equity category with an average
ALTAR Score™ of 6.6% and a standard deviation
of 1.5%. PSIL's ALTAR Score™ is approximately -0.6 standard
deviations above the category average. This places PSIL in the 27th percentile
among funds in the category.
Sell-Side Consensus
$32.85
PRICE TARGET
+55.9%
UPSIDE